Clinical trials: Unresectable or Metastatic Melanoma
- Condition Unresectable or Metastatic Melanoma
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Metastatic Melanoma
A Study of Tasisulam in Treating Participants With Malignant Melanoma
The primary purpose of this study is to determine the objective response rate (complete and partial response) for participants who receive tasisulam after one prior systemic treatment for unresectable or metastatic melanoma.
- Trial name
- NCT00383292
- Testing
- tasisulam
- Where
- 13 sites in United States, Australia
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Unresectable Melanoma, Metastatic Melanoma
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or…
- Trial name
- CheckMate 069 (NCT01927419)
- Testing
- Nivolumab, Ipilimumab
- Where
- 21 sites in United States, France
- Volunteers
- 142 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
This was a two-arm, double-blinded, randomized, Phase III study comparing dabrafenib and trametinib combination therapy to dabrafenib administered with a placebo (dabrafenib monotherapy).
- Trial name
- NCT01584648
- Testing
- Dabrafenib, Trametinib
- Where
- 121 sites in United States, Argentina and 12 more
- Volunteers
- 423 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
The purpose of this study is to compare the clinical benefit, as measured by overall survival, of nivolumab with that of. dacarbazine in patients with previously untreated, unresectable, or metastatic melanoma
- Trial name
- CheckMate 066 (NCT01721772)
- Testing
- BMS-936558 (Nivolumab), Dacarbazine
- Where
- 75 sites in Argentina, Australia and 14 more
- Volunteers
- 418 people
- Sponsor
- Bristol-Myers Squibb
Malignant Melanoma, Squamous Cell Carcinoma of Skin
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Primary Objective: -To determine the antitumor activity of SAR444245 in combination with cemiplimab. Secondary Objectives: To determine the recommended phase 2 dose and to assess the safety profile of SAR444245 when combined with…
- Trial name
- NCT04913220
- Testing
- THOR-707, Cemiplimab
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 46 people
- Sponsor
- Sanofi
Unresectable Stage III, Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
The purpose of this study is to assess the objective response rate of lenvatinib in previously treated participants with American Joint Committee on Cancer (AJCC) unresectable Stage III or Stage IV melanoma and disease…
- Trial name
- NCT01136967
- Testing
- Lenvatinib
- Where
- 95 sites in United States, Australia and 2 more
- Volunteers
- 182 people
- Sponsor
- Eisai Inc.
Melanoma
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
The purpose of this study is to determine whether giving Ipilimumab at a dose of 10mg/kg will extend the lives of subjects with unresectable or metastatic melanoma more than giving Ipilimumab at a dose of 3 mg/kg
- Trial name
- NCT01515189
- Testing
- Ipilimumab
- Where
- 88 sites in United States, Argentina and 20 more
- Volunteers
- 831 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
The purpose of this study was to evaluate safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with BRAF V600 mutant, unresectable…
- Trial name
- COMBI-i (NCT02967692)
- Testing
- Spartalizumab, Dabrafenib, Trametinib
- Where
- 179 sites in United States, Argentina and 27 more
- Volunteers
- 568 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Cancer
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient's specific tumour type.
- Trial name
- MODULATE (NCT03009058)
- Testing
- IMM-101, Gemcitabine, Nab-paclitaxel
- Where
- 4 sites in France, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Immodulon Therapeutics Ltd
Malignant Melanoma
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
This open-label, dose-escalation study of vemurafenib in combination with cobimetinib will evaluate the safety, tolerability and pharmacokinetics in participants with BRAFV600 mutation-positive metastatic melanoma.
- Trial name
- NCT01271803
- Testing
- Cobimetinib, vemurafenib
- Where
- 10 sites in United States, Australia
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy with vemurafenib.
- Trial name
- COMBI-v (NCT01597908)
- Testing
- Dabrafenib, Vemurafenib, Trametinib
- Where
- 205 sites in United States, Argentina and 26 more
- Volunteers
- 704 people
- Sponsor
- Novartis Pharmaceuticals
Unresectable or Metastatic Melanoma
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
- Trial name
- NCT01721746
- Testing
- BMS-936558, Dacarbazine, Carboplatin
- Where
- 95 sites in United States, Austria and 12 more
- Volunteers
- 405 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
This is a multicenter, open-label, Phase 1b/2 study which will be conducted in two parts: a Phase 1b part comprising a dose escalation and an expansion cohort; and a Phase 2 part which will comprise two cohorts.
- Trial name
- NCT01433991
- Testing
- Golvatinib, Lenvatinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Eisai Inc.
Melanoma
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
This study will examine the effectiveness and safety of glembatumumab vedotin as monotherapy or in combination with immunotherapies in patients with advanced melanoma.
- Trial name
- NCT02302339
- Testing
- glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
- Where
- 14 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected).
- Trial name
- NCT03655756
- Testing
- IFx-Hu2.0
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- TuHURA Biosciences, Inc.
Melanoma
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma.
- Trial name
- NCT04091217
- Testing
- Atezolizumab, Bevacizumab
- Where
- 3 sites in China
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Melanoma (Skin), Cutaneous Melanoma
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or…
- Conditions
- Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor
- Trial name
- NCT05578872
- Testing
- ANV419
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 29 people
- Sponsor
- Anaveon AG
Melanoma
Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients
The purpose of this study is to assess the safety of Ipilimumab monotherapy in Japanese subjects with advanced melanoma
- Trial name
- NCT01990859
- Testing
- Ipilimumab
- Where
- 6 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
The purpose of this study is to determine the rate and frequency of high-grade (CTCAE v4.0 Grade 3 or higher), treatment-related, select adverse events in subjects with histologically confirmed stage III (unresectable) or stage…
- Trial name
- NCT02156804
- Testing
- Nivolumab (BMS-936558)
- Where
- 170 sites in Austria, Belgium and 18 more
- Volunteers
- 1,009 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors, Metastatic Melanoma
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and multiple oral doses of encorafenib in combination with binimetinib on the single oral dose pharmacokinetics (PK) of cytochrome P450 (CYP)…
- Trial name
- NCT03864042
- Testing
- losartan, dextromethorphan, caffeine
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 56 people
- Sponsor
- Pfizer